AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions
Phase Ia Clinical Trial Evaluating the Safety, Tolerability, and Primary Efficacy of AVL-102 in Patients With High-grade Intraepithelial Lesions Associated With Untreated HPV16/18/52/58 Infection.
This study was designed to evaluate the safety, tolerability, and efficacy of AVL-102 Injection in the treatment of high-grade cervical intraepithelial neoplasia (CIN2/3) caused by HPV 16/18/52/58 infection.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Mingli Li
- 電話番号:+86 18310917293
- メール:minglili@aeonvital.com
研究場所
-
-
Beijing Municipality
-
Xicheng、Beijing Municipality、中国、100044
- 募集
- Peking University People's Hospital
-
コンタクト:
- Xiuli Sun
- 電話番号:+86 18611661856
- メール:sunxiuli@pku.edu.cn
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Women aged 18-64 (inclusive) .
- Participants voluntarily joined the study and signed informed consent forms.
- During the screening period, if there are no clinically significant abnormalities in medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory test results, the researchers will determine that the candidate is suitable for enrollment .
- Patients whose screening pathology results confirm HPV types 16 and/or 18 and/or 52 and/or 58 (with or without non-high-risk subtypes, excluding high-risk subtypes 31, 33, 35, 39, 45, 51, 56, 59, 66, 68), evidence of cervical intraepithelial lesion CIN2/3, and who have not received standard treatment.
- Eligible trial participants of childbearing age (defined as women who have not undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy and have not been menopausal for ≥12 months) must agree to use highly effective contraception (such as oral contraceptives, intrauterine devices, barrier contraception combined with spermicide, or partner sterilization) with their partners during the study treatment period and for at least 12 months after the last dose.
- During the screening period, trial participants were not pregnant or breastfeeding and were willing to undergo additional pregnancy testing as required throughout the trial.
- Willing and able to comply with and complete all research procedures.
Exclusion criteria:
- Any skin condition on the upper arm that may interfere with the assessment of injection site reaction (ISR), including but not limited to large tattoos, scars, rashes, infections, or wounds.
- There was a severe venous defect, making it impossible to collect the blood sample required by the protocol.
- The screening criteria included acute infections of the genital tract or anus requiring systemic anti-infective treatment (excluding HPV infection).
- Those who are pregnant or breastfeeding, or who have a history of miscarriage within 3 months prior to screening.
- Medical conditions that, in the researchers' judgment, would increase the risk of bleeding during a biopsy.
- In addition to the study indication, patients with any clinically significant acute or chronic disease that, in the investigator's opinion, may increase the risk of exposure to the investigational drug or interfere with the study evaluation.
- Individuals who are not suitable for a full colposcopy evaluation.
- Any of the following situations exist:
1)The pathology of the target lesion during the screening period confirmed adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma; 2)of the cervix , vagina , vulva , or anus ; 3)During the screening period, microscopic examination revealed a suspected malignant tumor .
4)Having undergone a total hysterectomy and therefore unable to assess cervical lesions ; 5)excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc. ) in locations other than those mentioned above within the 5 years prior to enrollment .
9.Immunosuppressants used continuously (for more than 7 days ) within 30 days prior to screening , including but not limited to: Glucocorticoids (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.
10.Those who have received a known anti-HPV drug (including HPV prophylactic vaccine) within 30 days prior to screening.
11.Those who have previously undergone surgery or physical therapy for high-grade intraepithelial lesions, including but not limited to: loop electrosurgical excision procedure (LEEP), cold knife conization (CKC), laser ablation/resection, cryotherapy, electrocautery, photodynamic therapy, microwave therapy, focused ultrasound therapy, and other invasive/minimally invasive resection or ablation treatments targeting the lesion tissue.
12.A history of severe allergies (requiring hospitalization), a severe reaction to any medication or vaccine injection, or any known or suspected allergy to any component of an investigational drug or preparation.
13.Individuals with uncontrolled systemic chronic diseases. 14.The screening period laboratory tests meet any of the following criteria:
- Hemoglobin < 90 g/L;
- Neutrophil count < 1.0 × 10⁹ /L;
- Platelet count < 80 × 10⁹ /L;
- AST or ALT > 1.5×ULN;
- Creatinine clearance < 60 mL/min (Cockcroft-Gault formula);
- International Normalized Ratio (INR) > 1.5 × ULN;
- Positive for HIV antibodies;
- HCV antibody positive (and HCV RNA positive);
- HBsAg positive (and HBV DNA positive);
- Active syphilis (RPR/TPPA positive and requiring treatment). 15.Researchers believe there may be a history of alcohol or drug abuse that could affect the safety or compliance of trial participants .
16.Researchers consider participants who are unwilling or unable to comply with the requirements of the research protocol to be experimental participants.
Alternative criteria for trial participants :
To ensure the scientific validity and reliability of the experimental data, supplementary trials may be conducted by recruiting new participants if the following situations occur during the research process :
- If the researchers determine that there are other circumstances that make it unsuitable to continue AVL-102 injection before the injection, the participant will withdraw from the study, and a replacement participant may be selected through a new screening process.
- If a participant fails to complete three doses of AVL-102 injection or withdraws for any reason (excluding DLT reasons) and thus fails to complete the DLT assessment, a replacement participant can be selected through a new screening process.
Exit criteria:
Participants have the right to voluntarily withdraw from the study treatment at any time. Furthermore, the investigator may decide to withdraw a participant from the study treatment if the participant meets the following withdrawal criteria :
- DLT occurs;
- In cases where an adverse event (AE) or a serious adverse event (SAE) occurs, and the investigator determines that it is necessary to withdraw from the study;
- Participants in the trial had pre-existing high-grade intraepithelial lesions that progressed or became cancerous;
- The trial participants had poor compliance and were unable to participate in the treatment, visits, and follow-ups specified in the study, or were lost to follow-up.
- The trial participants insisted on withdrawing their informed consent and requested to withdraw from the trial;
- Other situations where researchers deem it inappropriate for participants to continue in the trial.
For each trial participant who discontinues study treatment , the investigator must record all required details in the electronic case report form (eCRF), including the date and reason for treatment discontinuation. Before withdrawing from the study, trial participants who discontinue study treatment must complete all examinations required for the final visit as specified in the trial protocol and undergo the corresponding follow-up. For all trial participants who withdraw from the study due to adverse events , follow-up must be conducted until the event is resolved, stabilized, returns to baseline levels, is attributable to a cause other than the study drug, or if further information is unavailable. The results must be recorded in the eCRF (and, after database locking, the follow-up results should be recorded in the original files at the research institution).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:AVL-102 Q3W×3
|
A total of 3 injections of AVL-102 are to be administered, with an interval of three weeks between each. The drug is to be given via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the recipient must remain under observation for 60 minutes, during which time a safety assessment will be conducted. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Dose-limiting toxicities (DLT),incidence and severity of adverse events, etc.
時間枠:Up to day 300
|
Up to day 300
|
|
Maximum tolerated dose (MTD) and RDE
時間枠:Up to day 300
|
Up to day 300
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Geometric Mean Titer (GMT) of Anti-HPV16/18/52/58 Antigen-Specific Antibodies
時間枠:Up to day 300
|
Humoral immune response evaluated by measuring serum antigen-specific antibody titers against HPV types 16, 18, 52, and 58 using Enzyme-Linked Immunosorbent Assay (ELISA). |
Up to day 300
|
|
Cell-Mediated Specific Immune Response Against HPV16/18/52/58 Antigens
時間枠:Up to Day 300
|
Cellular immune response evaluated by measuring the number of IFN-γ secreting antigen-specific T cells per million peripheral blood mononuclear cells (PBMCs) using Enzyme-Linked Immunospot (ELISpot) assay, reported as Spot Forming Cells (SFCs)/10^6 PBMCs. |
Up to Day 300
|
|
Validity
時間枠:Up to day 300
|
|
Up to day 300
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory endpoint indicators-Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax)
時間枠:Up to day 43
|
Peak plasma concentration of the study drug measured after administration (Unit: ng/mL) |
Up to day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Time to Reach Maximum Observed Plasma Concentration (Tmax)
時間枠:Up to day 43
|
Time elapsed from drug administration to reach Cmax (Unit: hours). |
Up to day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration (AUC0-t)
時間枠:Up to day 43
|
Calculated using the linear trapezoidal method from time 0 to the last measurable concentration time point (Unit: h*ng/mL). |
Up to day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-∞)
時間枠:Up to Day 43
|
Calculated as AUC0-t plus the extrapolated area from the last measurable concentration to infinity (Unit: h*ng/mL). |
Up to Day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Terminal Elimination Half-Life (t1/2)
時間枠:Up to Day 43
|
Time required for the plasma concentration of the drug to decrease by 50% during the terminal elimination phase (Unit: hours). |
Up to Day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Mean Residence Time (MRT)
時間枠:Up to Day 43
|
Average time the drug molecules stay in the body after administration (Unit: hours). |
Up to Day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Total Plasma Clearance (CL)
時間枠:Up to Day 43
|
Volume of plasma from which the drug is completely removed per unit time (Unit: L/h). |
Up to Day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Terminal Elimination Rate Constant (λz)
時間枠:Up to Day 43
|
First-order rate constant associated with the terminal (log-linear) portion of the concentration-time curve (Unit: 1/h). |
Up to Day 43
|
|
Exploratory endpoint indicators-Pharmacokinetics-Apparent Volume of Distribution (Vd)
時間枠:Up to Day 43
|
Theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma (Unit: L). |
Up to Day 43
|
|
Exploratory endpoint indicators-Cytokines
時間枠:Up to day 300
|
Expression level of IL-1β, IL-2, IL-6, IL-10, GM-CSF, TNF-α and IFN-γ |
Up to day 300
|
|
Exploratory endpoint indicators-PEG antibody
時間枠:Up to day 126
|
Anti-polyethylene glycol (PEG) antibody response: Serum anti-PEG IgG and anti-PEG IgM titers were measured by enzyme-linked immunosorbent assay (ELISA) to assess the potential association between the immunogenicity of the PEGylated lipid components in LNP and its adverse reactions after repeated administration. |
Up to day 126
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- AVL-102-CN-Ia
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。